Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568477 | 0.95 | SIGMAR1 (0.53) | L3MBTL1SIGMAR1SLC6A5MCHR1ACHE | |
| Hydrochloric Acid SCHEMBL1243957 | 0.93 | SIGMAR1 (0.52) | L3MBTL1SIGMAR1SLC6A5MCHR1ACHE | |
| Hydrogen Peroxide SCHEMBL27308227 | 0.92 | SIGMAR1 (0.50) | L3MBTL1HRH3SIGMAR1SLC6A5ACHE | |
| Hydrochloric Acid SCHEMBL2346749 | 0.92 | SIGMAR1 (0.50) | L3MBTL1SIGMAR1SLC6A5MCHR1ACHE | |
| Hydrochloric Acid SCHEMBL16760314 | 0.92 | SIGMAR1 (0.50) | L3MBTL1SIGMAR1SLC6A5MCHR1ACHE | |
| SCHEMBL4055438 | 0.88 | HRH3 (0.59) | L3MBTL1HRH3SIGMAR1MCHR1CXCR4 | |
| SCHEMBL266771 | 0.87 | SLC6A5 (0.59) | SIGMAR1SLC6A5ACHE | |
| SCHEMBL11172583 | 0.86 | HRH3 (0.57) | L3MBTL1HRH3SIGMAR1MCHR1CXCR4 | |
| Hydrochloric Acid SCHEMBL31714128 | 0.86 | SLC6A5 (0.57) | SIGMAR1SLC6A5ACHE | |
| SCHEMBL6557748 | 0.85 | ALDH1A1 (0.66) | L3MBTL1HRH3SIGMAR1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| WO-2024046221-A1 | EGFR INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-03-07 | — | — | WO | disclosed |
| EP-3246317-B1 | BTK INHIBITOR | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-2069327-B1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
| WO-2008022979-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1806347-A1 | AROMATIC-RING-FUSED PYRIMIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1803710-A1 | PYRIMIDINE DERIVATIVE CONDENSED WITH NON-AROMATIC RING | Astellas Pharma Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| EP-1608662-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083218-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-09-30 | — | — | WO | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | L3MBTL1 2099/4885HRH3 3404/4885SIGMAR1 4559/4885 |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | L3MBTL1 41/4885HRH3 1645/4885SIGMAR1 1602/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | L3MBTL1 41/4885HRH3 1645/4885SIGMAR1 1602/4885 |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | L3MBTL1 2365/4885HRH3 200/4885SIGMAR1 365/4885 |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | GPR119, NOD1, IRS1 | L3MBTL1 3154/4885HRH3 2122/4885SIGMAR1 1814/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | L3MBTL1 1142/4885HRH3 1124/4885SIGMAR1 453/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | L3MBTL1 2099/4885HRH3 3404/4885SIGMAR1 4559/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | L3MBTL1 41/4885HRH3 1645/4885SIGMAR1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.